QSI is Quantum-Si Incorporated, a Branford, Connecticut-based proteomics company developing benchtop, single-molecule protein-sequencing instruments, consumables and analysis software sold under its Platinum and Proteus brands. The stock is up 14.85% on the session, trading at $1.16 against a prior close of $1.01, with the direction firmly to the upside. The immediate reason is unambiguous: before the opening bell, Quantum-Si said it had detected all 20 standard amino acids in its Proteus development program, a technical benchmark the company had targeted for the end of 2026. The stock gapped higher at the open, touched $1.21, and has held most of the gain.
Proteins are built from a 20-letter alphabet of amino acids, and reading protein sequence requires distinguishing every one of them — the equivalent of calling all four nucleotide bases in DNA sequencing. Quantum-Si said it has now demonstrated detection of the complete set at the single-molecule level inside its Proteus development program, four months ahead of its own deadline and after disclosing 18- and then 19-amino-acid coverage at earlier checkpoints in September and October.
Management framed the result as a platform-defining proof of chemistry rather than a commercial event. Chief Executive Jeff Hawkins described it as a foundational benchmark that could support reference-free protein identification and broader analysis of proteoforms, sequence variants and post-translational modifications. For a development-stage company whose trailing revenue is barely above $1 million, that is precisely the kind of de-risking signal investors have been paying for.
The context matters, however. Quantum-Si is now working to fold 20-amino-acid detection into a developmental sequencing kit for Proteus instruments, and commercialization of the platform itself has already slipped to the second quarter of 2027 from an earlier end-of-2026 target, with management citing instrument reproducibility, manufacturing yields and component supply. Today's news validates the science, not the launch schedule or the revenue line.
The rally also has a mechanical component. QSI had fallen from a close of $1.75 on October 29 to $1.01 on November 17, a decline of roughly 42% that left the shares below their 20-session average and back near levels that previously triggered a Nasdaq minimum-bid issue. With short interest near 12.7 million shares as of the latest settlement data and float that trades lightly relative to larger peers, a fundamentally positive headline tends to produce an outsized percentage response. The pattern of double-digit single-session gains on milestone news is well established here — the October 8 disclosure of 19-amino-acid detection preceded a 25% jump.
Activity is clearly elevated. Roughly 3.2 million shares changed hands in the first 70 minutes of the session, close to half the average full-day volume of about 6.7 million shares, on a stock with a market value of roughly $255 million. The move opened with a gap and has held in a $1.15–$1.21 range since, which suggests a mix of new buyers and profit-taking rather than a single algorithmic spike.
The catalyst was company-specific, and the tape reflected that: no peer or sector-wide news accompanied the release, and the broad direction of small-cap life-sciences tools names did not drive the gain. Technically, the stock reclaimed the $1.10 area it lost in mid-November but remains below its 20-session average of roughly $1.32, leaving the mid-October breakdown zone as the next meaningful resistance reference.
The score runs from 0 to 100, where 0 means no meaningful news and a price move that is routine for the stock, and 100 means transformative news combined with an extreme, rare move. Quantum-Si earns 38 out of 100. The verified news was substantive but developmental — a technical milestone in a program whose commercial launch is still more than a year out, with no revenue or guidance impact — so it sits in the moderate-to-major band rather than the transformative one. The price move, at roughly 2.3 times the stock's typical daily swing of about 6.5%, was notable but not extraordinary: moves of similar or greater magnitude have occurred six times in the last 60 sessions. Strong-ish news and a moderately unusual move together produce the mid-30s score.
The next hard checkpoint is execution on the developmental kit, with management promising additional Proteus performance data as that work progresses. Investors will also press for clarity on the Q2 2027 launch timeline, manufacturing yields and the pricing strategy for a platform that must displace entrenched mass-spectrometry workflows.
On the financial side, the company reports fourth-quarter and full-year results in the first quarter of 2027; the third quarter brought a narrower-than-expected loss but revenue of just $0.21 million, well short of expectations. Cash of roughly $103 million gives runway, but dilution risk remains a structural feature of the story. Analyst coverage is thin, with a consensus leaning constructive and a wide spread of targets. Risks include further launch delays, competitive pressure from larger tools makers and other protein-sequencing entrants, and the volatility inherent to a sub-$2 stock with a small float.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ widely by strategy logic, holding period, risk profile, performance metrics and the symbols they trade, so the featured list changes as market conditions evolve. It is a practical starting point for traders who want to see which approaches are working right now rather than sifting through the full catalogue. Review the current leaders and compare them against your own process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 160 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 100 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The 10-day RSI Indicator for QSI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 25 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QSI as a result. In 78 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
QSI moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.616) is normal, around the industry mean (4.142). P/E Ratio (-2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices